Harvard Bioscience Receives "Notice of Allowability" from US Patent Office for Key Model Organism Sorter Technology
HOLLISTON, Mass., Oct 16, 2001 /PRNewswire via COMTEX/ -- Today Harvard Bioscience, Inc. (Nasdaq: HBIO) announced the receipt of a "Notice of Allowability" from the United States Patent and Trademark Office (USPTO) for its key model organism sorting technology, known as COPAS. The COPAS technology enables the high throughput/high content analysis and sorting of model organisms such as the fruit fly, D. melanogaster, the nematode worm, C. elegans, and the zebrafish, D. rerio. These model organisms are increasingly being used by pharmaceutical and biotechnology companies for target validation, efficacy screening and ADMET screening in drug discovery, and by university researchers in basic genetic and genomic research. The COPAS technology can also be used to sort beads used in combinatorial chemistry at record speeds such as in the recently announced work with the Carlsberg Institute. COPAS instruments and systems are sold through Harvard Bioscience's Union Biometrica subsidiary.
David Green, President of Harvard Bioscience commented: "We are very pleased to receive this "Notice of Allowability". It confirms the uniqueness of the inventions we have made for high throughput drug discovery. This is only one of several patent applications we have before the USPTO."
About Harvard Bioscience, Inc.
Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries though its direct sales force, 1,000 page catalog, and through its distributors, the most notable of which is AP Biotech. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany and Belgium with sales facilities in France and Canada. For more information please visit www.harvardbioscience.com or www.unionbio.com
The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements about the possible effect of our technology on the drug development process, the Company's ability to get and maintain patent protection for its inventions and the Company's plans, objectives and intentions contained in this press release that are not historical facts. Other factors that may cause the Company's actual results to differ materially from those in the forward looking statements include those set forth under the heading "Important Factors That May Affect Future Operating Results" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, as well as other risks described in the Company's public filings or factors, if any, of which the Company is not currently aware. The Company may not update these forward- looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X25397659
SOURCE Harvard Bioscience, Inc.
CONTACT: David Green, President, Harvard Bioscience, +1-508-893-8999,
dgreen@harvardbioscience.com
URL: http://www.harvardbioscience.com
http://www.prnewswire.com
Copyright (C) 2001 PR Newswire. All rights reserved.
Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.